reports
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Co...
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio...
TELA Bio to Announce Second Quarter 2025 Financial Results
TELA Bio to Announce Second Quarter 2025 Financial Results MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInves...
Rocky Mountain Chocolate Factory Reports First Quarter Fiscal 2026 Fin...
Rocky Mountain Chocolate Factory Reports First Quarter Fiscal 2026 Financial Results Management to Host Conference Call Tomorrow at 9:00 a.m. Eastern Time DURANGO, Colo., July 15, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “we”, “RMC”, or “Rocky Mountain Chocolate”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, is reporting financial and operating results for its first quarter of fiscal 2026, which ended May 31, 2025. “We are executing against a clearly defined plan...
Rocky Mountain Chocolate Factory Recruits Luis Burgos as Vice Presiden...
Rocky Mountain Chocolate Factory Recruits Luis Burgos as Vice President of Operations DURANGO, Colo., July 14, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, today announced the appointment of Luis Burgos as Vice President of Operations. Mr. Burgos is a seasoned operations executive with more than 29 years of experience leading large-scale manufacturing and distribution operations. He has held senior leadership ro...
Rocky Mountain Chocolate Factory Schedules Fiscal First Quarter 2026 C...
Rocky Mountain Chocolate Factory Schedules Fiscal First Quarter 2026 Conference Call for July 16, 2025 at 9:00 A.M. ET DURANGO, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, will host a conference call on Wednesday, July 16, 2025 at 9:00 a.m. Eastern time to discuss its fiscal first quarter 2026 results. The Company’s results will be reported in a press release prior to the call. The RMCF managemen...
Rocky Mountain Chocolate Factory Regains Compliance with Nasdaq Listin...
Rocky Mountain Chocolate Factory Regains Compliance with Nasdaq Listing Requirements DURANGO, Colo., June 25, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s ChocolatierTM and a leading franchiser of a premium chocolate and confectionary retail store concept, announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Annual Report on Form 10-K for the fiscal year ended February 28, 2025. Nasdaq Listing Rule 5250(c)(1) requires listed companies to file all required annu...
Rocky Mountain Chocolate Factory Reports Fiscal Fourth Quarter and Fis...
Rocky Mountain Chocolate Factory Reports Fiscal Fourth Quarter and Fiscal Year 2025 Financial Results Management to Host Conference Call Tomorrow at 9:00 a.m. ET DURANGO, Colo., June 17, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, “RMC”, or “Rocky Mountain Chocolate”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, is reporting financial and operating results for its fiscal fourth quarter and fiscal year ended February 28, 2025. “Fiscal 2025 marked the beginning of a ...
Rocky Mountain Chocolate Factory Schedules Fiscal Fourth Quarter and F...
Rocky Mountain Chocolate Factory Schedules Fiscal Fourth Quarter and Full Year 2025 Conference Call for June 18, 2025 at 9:00 A.M. ET DURANGO, Colo., June 17, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, will host a conference call on Wednesday, June 18, 2025 at 9:00 a.m. Eastern time to discuss its fiscal fourth quarter and full year 2025 results. The Company’s results will be reported in a press release prior to...
Paycom Software Inc: 1 director
A director at Paycom Software Inc sold 1,500 shares at 249.959USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units coveri...
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for ...
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair Based on market research, inguinal hernia repair is the most common type of hernia repair MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. T...
TELA Bio Appoints Jeffrey Blizard as President
TELA Bio Appoints Jeffrey Blizard as President Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio’s Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. “...
Rocky Mountain Chocolate Factory Launches First Fully Redesigned Store...
Rocky Mountain Chocolate Factory Launches First Fully Redesigned Store in Charleston, South Carolina DURANGO, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, is proud to announce the grand opening of its first fully redesigned store, located at 415 King Street in the heart of Charleston, South Carolina. The new location opens to the public on June 3, 2025, marking the Company’s first presence in the s...
Rocky Mountain Chocolate Factory Announces Intention to File Form 12b-...
Rocky Mountain Chocolate Factory Announces Intention to File Form 12b-25 and Delay Its Fiscal Year 2025 Earnings Release and Conference Call DURANGO, Colo., May 27, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, today announced that it intends to file a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission with regard to its annual report on Form 10-K (the “Fiscal 2025 10-K”) for the ...
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Confer...
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA’s management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, Inc.TELA Bio, ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuan...
TELA Bio Reports First Quarter 2025 Financial Results
TELA Bio Reports First Quarter 2025 Financial Results MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix product...
TELA Bio to Announce First Quarter 2025 Financial Results
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® P...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic...
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for O...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.